糖尿病性黄斑浮腫(Diabetic Macular Edema):治療薬パイプラインレビュー

◆英語タイトル:Diabetic Macular Edema - Pipeline Review, H2 2018
◆商品コード:GMDHC10643IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2018年7月17日
◆ページ数:231
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site PriceUSD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprise PriceUSD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Diabetic Macular Edema – Pipeline Review, H2 2018
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema – Pipeline Review, H2 2018, provides an overview of the Diabetic Macular Edema (Metabolic Disorders) pipeline landscape.

Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Diabetic Macular Edema – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Diabetic Macular Edema (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 19, 7, 2, 35 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Diabetic Macular Edema (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
Introduction 5
Diabetic Macular Edema – Overview 6
Diabetic Macular Edema – Therapeutics Development 7
Diabetic Macular Edema – Therapeutics Assessment 18
Diabetic Macular Edema – Companies Involved in Therapeutics Development 27
Diabetic Macular Edema – Drug Profiles 49
Diabetic Macular Edema – Dormant Projects 208
Diabetic Macular Edema – Discontinued Products 211
Diabetic Macular Edema – Product Development Milestones 212
Appendix 222

List of Tables
Number of Products under Development for Diabetic Macular Edema, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Diabetic Macular Edema - Pipeline by Abpro, H2 2018
Diabetic Macular Edema - Pipeline by Aciont Inc, H2 2018
Diabetic Macular Edema - Pipeline by Acucela Inc, H2 2018
Diabetic Macular Edema - Pipeline by Aerie Pharmaceuticals Inc, H2 2018
Diabetic Macular Edema - Pipeline by Aldeyra Therapeutics Inc, H2 2018
Diabetic Macular Edema - Pipeline by Allergan Plc, H2 2018
Diabetic Macular Edema - Pipeline by Allgenesis Biotherapeutics Inc, H2 2018
Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals Inc, H2 2018
Diabetic Macular Edema - Pipeline by Araim Pharmaceuticals Inc, H2 2018
Diabetic Macular Edema - Pipeline by Boehringer Ingelheim GmbH, H2 2018
Diabetic Macular Edema - Pipeline by Cell Medica Ltd, H2 2018
Diabetic Macular Edema - Pipeline by Celon Pharma SA, H2 2018
Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2018
Diabetic Macular Edema - Pipeline by Clearside BioMedical Inc, H2 2018
Diabetic Macular Edema - Pipeline by Coherus BioSciences Inc, H2 2018
Diabetic Macular Edema - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Diabetic Macular Edema - Pipeline by Elasmogen Ltd, H2 2018
Diabetic Macular Edema - Pipeline by Exonate Ltd, H2 2018
Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals Inc, H2 2018
Diabetic Macular Edema - Pipeline by EyePoint Pharmaceuticals Inc, H2 2018
Diabetic Macular Edema - Pipeline by Eyevensys SAS, H2 2018
Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Diabetic Macular Edema - Pipeline by Formycon AG, H2 2018
Diabetic Macular Edema - Pipeline by Gene Signal International SA, H2 2018
Diabetic Macular Edema - Pipeline by Genmab A/S, H2 2018
Diabetic Macular Edema - Pipeline by Graybug Vision Inc, H2 2018
Diabetic Macular Edema - Pipeline by Isarna Therapeutics GmbH, H2 2018
Diabetic Macular Edema - Pipeline by Kalvista Pharmaceuticals Inc, H2 2018
Diabetic Macular Edema - Pipeline by Kowa Co Ltd, H2 2018
Diabetic Macular Edema - Pipeline by Lupin Ltd, H2 2018
Diabetic Macular Edema - Pipeline by Mabion SA, H2 2018
Diabetic Macular Edema - Pipeline by Momenta Pharmaceuticals Inc, H2 2018
Diabetic Macular Edema - Pipeline by Novartis AG, H2 2018
Diabetic Macular Edema - Pipeline by Ocular Therapeutix Inc, H2 2018
Diabetic Macular Edema - Pipeline by Oculis ehf, H2 2018
Diabetic Macular Edema - Pipeline by OcuNexus Therapeutics Inc, H2 2018
Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc, H2 2018
Diabetic Macular Edema - Pipeline by Pfizer Inc, H2 2018
Diabetic Macular Edema - Pipeline by Profarma, H2 2018
Diabetic Macular Edema - Pipeline by Protheragen Inc, H2 2018
Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Diabetic Macular Edema - Pipeline by Rezolute Inc, H2 2018
Diabetic Macular Edema - Pipeline by SciFluor Life Sciences LLC, H2 2018
Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co Ltd, H2 2018
Diabetic Macular Edema - Pipeline by Stealth BioTherapeutics Inc, H2 2018
Diabetic Macular Edema - Pipeline by ThromboGenics NV, H2 2018
Diabetic Macular Edema - Pipeline by Unity Biotechnology Inc, H2 2018
Diabetic Macular Edema - Pipeline by Verseon Corp, H2 2018
Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, H2 2018
Diabetic Macular Edema - Dormant Projects, H2 2018
Diabetic Macular Edema - Dormant Projects, H2 2018 (Contd..1), H2 2018
Diabetic Macular Edema - Dormant Projects, H2 2018 (Contd..2), H2 2018
Diabetic Macular Edema - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Diabetic Macular Edema, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[糖尿病性黄斑浮腫(Diabetic Macular Edema):治療薬パイプラインレビュー]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆